Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vaccine Delay Putting Millions of Japanese Children at Risk (Japan)

This article was originally published in PharmAsia News

Executive Summary

Pharmaceutical companies working on a safer vaccine for Japanese encephalitis (JE) are not expected to have a new vaccine shot ready until 2009, which is putting Japanese children at risk. Two companies currently working on a new vaccine have reported adverse side-effects unacceptable in the widespread usage. Japan's government halted vaccination for JE in 2005 after a student became critically ill from the previously-approved inoculation regimen. JE is a viral illness attacking the nervous system. It is spread by mosquitoes who have feasted on pigs and then bite and infect humans. JE is fatal in 20 percent to 40 percent of cases. In September 2006, one three-year-old developed JE, the first person under six to report having the disease since 1991. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC066385

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel